NCT07478536Not yet recruiting
Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)
Summary
The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance). The goal is to see if this test can help doctors safely follow patients with fewer invasive procedures, such as repeated biopsies.
Inclusion criteria
• Adult Men ≥ 18 y. o. • Men with low-risk prostate cancer (D'Amico risk classification) currently undergoing Active Surveillance (AS) • First inclusion in Active Surveillance (AS) after 1st January 2022. • Scheduled for follow-up with systematic and/or Magnetic Resonance Imaging (MRI)-targeted (fusion) prostate biopsies - Prostate Magnetic Resonance Imaging (MRI) performed within the past three months available
Exclusion criteria
• \- Prior prostate cancer treatment (surgery, radiation, chemotherapy, hormonal therapy). • Patient with intermediate- or high-risk prostate cancer • Urinary catheterization within the past 6-8 weeks • Contraindications to Magnetic Resonance Imaging (MRI) or biopsy
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Not yet recruiting
- Phase
- —
- Study type
- Observational
- Countries
- Switzerland
- Sponsor
- Insel Gruppe AG, University Hospital Bern(Other)
- Protocol no.
- CHAS3-2026-NG-001
- Conditions
- Prostate Cancer, Active Surveillance for Prostate Cancer
- Interventions
- Diagnostic test
Treatments studied
- Stockholm3
Locations · 1
- Bern, SwitzerlandInselspital, University Hospital of BernNot yet recruiting at this site
In total, worldwide, the only site listed in the registry is planned; recruitment has not opened yet.
Site status per the ClinicalTrials.gov registry (last update posted: June 22, 2026).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.